Profile Response Detail

Molecular Profile ERBB2 negative
Therapy Exemestane + Seribantumab
Indication/Tumor Type Her2-receptor negative breast cancer
Response Type predicted - sensitive
Create By tyin
Update By djd


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
ERBB2 negative Her2-receptor negative breast cancer predicted - sensitive Exemestane + Seribantumab Phase II Actionable In a Phase II trial, Seribantumab (MM-12) and Aromasin (exemestane) combination treatment resulted in a 74% decrease in risk of progression (HR 0.26) and a a 59% decrease in risk of death (HR 0.436) compared to exemestane alone in ERBB2-negative, hormone receptor positive breast cancer patients (AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer, May 2016, Abstract # A14). detail...
PubMed Id Reference Title Details
Identification of heregulin expression as a driver of a difficult-to-treat cancer phenotype and development of a prospective companion diagnostic for the heregulin-ErbB3 targeting drug seribantumab Full reference...